We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Single-Dose Intravenous Melphalan in Advanced Multiple Myeloma.
- Authors
Bäck, Hans; Lindblad, Ragnar; Rödjer, Stig; Westin, Jan
- Abstract
Eight patients with progressive multiple myeloma were given an intermediate intravenous dose of melphalan (30 mg/m2). A response lasting 2-18 months was observed in 7 patients. The bone marrow toxicity was well acceptable and most courses could be given on an outpatient basis. Intermediate-dose intravenous melphalan may be considered an alternative for treatment of relapsing or progressive multiple myeloma, even if the patient has previously received oral melphalan. Copyright © 1990 S. Karger AG, Basel
- Publication
Acta Haematologica, 1990, Vol 83, Issue 4, p183
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000205210